BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 15522999)

  • 1. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.
    Aracava Y; Pereira EF; Maelicke A; Albuquerque EX
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1195-205. PubMed ID: 15522999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.
    Gilling KE; Jatzke C; Parsons CG
    Neuropharmacology; 2007 Sep; 53(3):415-20. PubMed ID: 17632186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comments on "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons".
    Banerjee P; Samoriski G; Gupta S
    J Pharmacol Exp Ther; 2005 May; 313(2):928-9; author reply 930-3. PubMed ID: 15831445
    [No Abstract]   [Full Text] [Related]  

  • 5. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels.
    Mok MH; Fricker AC; Weil A; Kew JN
    Neuropharmacology; 2009 Sep; 57(3):242-9. PubMed ID: 19523966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA and AMPA receptors contribute to the nicotinic cholinergic excitation of CA1 interneurons in the rat hippocampus.
    Alkondon M; Pereira EF; Albuquerque EX
    J Neurophysiol; 2003 Sep; 90(3):1613-25. PubMed ID: 12702709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors.
    Plazas PV; Savino J; Kracun S; Gomez-Casati ME; Katz E; Parsons CG; Millar NS; Elgoyhen AB
    Eur J Pharmacol; 2007 Jul; 566(1-3):11-9. PubMed ID: 17466293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
    Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
    Gilling KE; Jatzke C; Hechenberger M; Parsons CG
    Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal.
    Barik J; Wonnacott S
    Mol Pharmacol; 2006 Feb; 69(2):618-28. PubMed ID: 16269536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinic receptor-mediated enhancement of long-term potentiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus.
    Welsby P; Rowan M; Anwyl R
    Eur J Neurosci; 2006 Dec; 24(11):3109-18. PubMed ID: 17156372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype-specific inhibition of nicotinic acetylcholine receptors by choline: a regulatory pathway.
    Alkondon M; Albuquerque EX
    J Pharmacol Exp Ther; 2006 Jul; 318(1):268-75. PubMed ID: 16565162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-methyl-D-aspartate receptor channel block by the enantiomeric 6,7-benzomorphans BIII 277 CL and BIII 281 CL.
    Grauert M; Rho JM; Subramaniam S; Rogawski MA
    J Pharmacol Exp Ther; 1998 May; 285(2):767-76. PubMed ID: 9580625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-nicotine ameliorates corticosterone's potentiation of N-methyl-d-aspartate receptor-mediated cornu ammonis 1 toxicity.
    Mulholland PJ; Self RL; Harris BR; Littleton JM; Prendergast MA
    Neuroscience; 2004; 125(3):671-82. PubMed ID: 15099681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
    Losi G; Lanza M; Makovec F; Artusi R; Caselli G; Puia G
    Neuropharmacology; 2006 Mar; 50(3):277-85. PubMed ID: 16236334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.
    Lopes C; Pereira EF; Wu HQ; Purushottamachar P; Njar V; Schwarcz R; Albuquerque EX
    J Pharmacol Exp Ther; 2007 Jul; 322(1):48-58. PubMed ID: 17446300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.
    Giorgetti M; Gibbons JA; Bernales S; Alfaro IE; Drieu La Rochelle C; Cremers T; Altar CA; Wronski R; Hutter-Paier B; Protter AA
    J Pharmacol Exp Ther; 2010 Jun; 333(3):748-57. PubMed ID: 20194526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
    Motawaj M; Burban A; Davenas E; Arrang JM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
    Priestley T; Marshall GR; Hill RG; Kemp JA
    Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.